Merit Medical Systems
What analysts say:
- Buy, sell, or hold?: Analysts strongly back Merit Medical Systems, with six out of seven rating it a buy and the remainder rating it a hold. Analysts don't like Merit Medical Systems as much as competitor ICU Medical overall. Analysts still rate the stock a moderate buy, but they are a bit more wary about it compared to three months ago.
- Revenue forecasts: On average, analysts predict $91.9 million in revenue this quarter. That would represent a rise of 13.1% from the year-ago quarter.
- Wall Street earnings expectations: The average analyst estimate is earnings of $0.19 per share. Estimates range from $0.18 to $0.19.
What our community says:
CAPS All-Stars are strongly backing the stock, with 100% giving it an outperform rating. The greater community agrees with the All-Stars, as 94.6% give it a rating of outperform. Even with a robust four out of five stars, Merit Medical Systems' CAPS rating falls a little short of the community's upbeat outlook.
The company boosted its gross margin by 2.7 percentage points in the last quarter. Revenue rose 23.6% while cost of sales rose 17.9% to $49.4 million from a year earlier.
We can help you keep tabs on your companies with My Watchlist, our free, personalized service. Add Merit Medical Systems now.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.Earnings estimates provided by Zacks.